Illumina (NASDAQ:ILMN) Stock Rating Lowered by Wall Street Zen

Illumina (NASDAQ:ILMN) was downgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report released on Saturday, Wall Street Zen reports.

Other analysts also recently issued research reports about the company. Canaccord Genuity Group raised their price objective on Illumina from $190.00 to $205.00 and gave the stock a “hold” rating in a research report on Monday, August 3rd. TD Cowen upped their target price on Illumina from $192.00 to $210.00 and gave the company a “hold” rating in a research note on Friday, July 31st. Sanford C. Bernstein reaffirmed a “market perform” rating and issued a $215.00 target price on shares of Illumina in a research report on Friday, July 31st. Barclays lifted their price target on shares of Illumina from $145.00 to $160.00 and gave the stock an “underweight” rating in a research note on Friday, July 31st. Finally, Zacks Research lowered shares of Illumina from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 1st. Ten research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $214.69.

Illumina Price Performance

Shares of Illumina stock opened at $273.04 on Friday. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40. The company has a market cap of $41.23 billion, a PE ratio of 50.94, a price-to-earnings-growth ratio of 3.87 and a beta of 1.41. The firm has a fifty day moving average price of $219.37 and a two-hundred day moving average price of $175.95. Illumina has a fifty-two week low of $88.00 and a fifty-two week high of $280.17.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.23 by $0.08. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The company had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. During the same quarter in the previous year, the firm posted $1.19 EPS. The business’s revenue was up 9.4% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Analysts expect that Illumina will post 5.36 EPS for the current year.

Insider Activity

In related news, Director Keith Meister sold 457,858 shares of the firm’s stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $200.10, for a total transaction of $91,617,385.80. Following the completion of the transaction, the director owned 2,372,694 shares in the company, valued at $474,776,069.40. This trade represents a 16.18% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last ninety days, insiders sold 2,061,850 shares of company stock valued at $436,479,102. Corporate insiders own 2.90% of the company’s stock.

Institutional Trading of Illumina

A number of large investors have recently bought and sold shares of ILMN. Fiduciary Financial Advisors acquired a new stake in shares of Illumina in the 2nd quarter valued at $26,000. MCF Advisors LLC grew its holdings in shares of Illumina by 172.4% in the 2nd quarter. MCF Advisors LLC now owns 158 shares of the life sciences company’s stock worth $28,000 after purchasing an additional 100 shares during the last quarter. Keating Financial Advisory Services Inc. acquired a new stake in shares of Illumina during the 2nd quarter worth about $32,000. Rakuten Securities Inc. bought a new position in Illumina during the 2nd quarter valued at about $33,000. Finally, Elevation Wealth Partners LLC lifted its holdings in Illumina by 52.5% during the 2nd quarter. Elevation Wealth Partners LLC now owns 244 shares of the life sciences company’s stock valued at $43,000 after purchasing an additional 84 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors.

About Illumina

Illumina, Inc develops and manufactures technologies used to analyze genetic variation and biological function. Its products are primarily based on next-generation sequencing, a method that enables researchers and clinicians to read DNA and RNA for applications including genomic research, disease studies, drug development and clinical testing.

The company offers sequencing instruments, consumables such as reagent kits and flow cells, and related software and informatics solutions. Illumina also provides services and support designed to help customers prepare samples, run sequencing workflows, interpret genomic data and integrate results into research or clinical operations.

Founded in 1998 and headquartered in San Diego, California, Illumina serves customers worldwide, including academic and government research institutions, pharmaceutical and biotechnology companies, hospitals, clinical laboratories and other healthcare organizations.